| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 28 Jan 2025 | 17 Jan 2025 |
| Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2024. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 January 2025 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31 December 2024 Outcome of the Board Meeting held on 28.01.2025 (As Per BSE Announcement dated on 28.01.2025) | ||
| Board Meeting | 25 Oct 2024 | 16 Oct 2024 |
| Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2024. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 October 2024 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Kindly take the above intimation on your record and oblige. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30 September 2024 (As Per BSE Announcement dated on 25.10.2024) | ||
| Board Meeting | 24 Jul 2024 | 16 Jul 2024 |
| Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2024 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2024. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 July 2024 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on 30 June 2024. Outcome Of The Board Meeting Held On 24.07.2024 (As per BSE Announcement Dated on 24/07/2024) | ||
| Board Meeting | 3 May 2024 | 24 Apr 2024 |
| Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/05/2024 ,inter alia, to consider and approve 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31 March 2024; 2. consider and recommend a final dividend, if any, on the equity shares of the Company for the financial year ended 31 March 2024, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. Further, in accordance with the Companys Code of Conduct for Prohibition of Insider Trading, the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 April 2024 till the expiry of 48 hours from the date the said financial results are made public. Board Meeting Outcome for Outcome Of The Board Meeting Held On 03.05.2024 1. Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended 31 March 2024. In this regard, please find enclosed: The Board Recommended a Final Dividend of Rs. 2/- (20%) per equity share of Rs. 10/- each fully paid (subject to deduction of tax, if any) on the equity share capital of Rs. 23,39,20,550/- (2,33,92,055 equity shares of Rs. 10/- each) for the financial year 2023-24. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. Audited Financial Results (Standalone and Consolidated) Of The Company For the Quarter And Financial Year Ended On 31 March 2024. (As Per BSE Announcement Dated on 03.05..2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
